LORI ENDICOTT-COOK: Open Payments
NPI 1801347000 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$752 in 35 payments from 13 companies in 2025. Trend: 2023 $297 · 2024 $482 · 2025 $752
Food & beverage: $752
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $248 |
| Merck Sharp & Dohme LLC | 5 | $117 |
| AstraZeneca Pharmaceuticals LP | 3 | $85 |
| Daiichi Sankyo Inc. | 3 | $73 |
| ABBVIE INC. | 2 | $47 |
| Legend Biotech USA Inc. | 2 | $38 |
| Adaptive Biotechnologies Corporation | 1 | $33 |
| Janssen Biotech, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
Products named: KISQALI, KEYTRUDA, SCEMBLIX, LYNPARZA, VENCLEXTA, Enhertu, CARVYKTI, clonoSEQ.
Industry payments across IN — which companies pay providers there.
